Patients with IKZF1-deleted HeH B-ALL had a 5-year EFS of 76% (versus 89% in IKZF1-non-deleted HeH B-ALL) even with MRD guided protocols, and IKZF1plus did not have an additional prognostic effect over IKZF1del alone [66]. The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.